GhandehariHKamal-BahlSWongND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J2008;156(1):112–9
2.
BaigentCKeechAKearneyPM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267–78
3.
PasternakRCSmithSCJr.Bairey-MerzCN. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol2002;40(3):567–72
4.
StaffaJAChangJGreenL. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med2002;346(7):539–40
5.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):7–22
6.
Lloyd-JonesDAdamsRCarnethonM. Heart disease and stroke statistics — 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2009;119(3):e21–181
7.
GroverSCoupalLLowensteynI. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?Can J Cardiol2008;24(12):891–8
8.
SchneckDWBirminghamBKZalikowskiJA. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther2004;75(5):455–63
KantolaTKivistoKTNeuvonenPJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther1998;64(2):177–82
11.
LinkEParishSArmitageJ. SLCO1B1 variants and statin-induced myopathy — a genomewide study. N Engl J Med2008;359(8):789–99
12.
AntonsKAWilliamsCDBakerSKPhillipsPS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med2006;119(5):400–9
13.
BottorffMHanstenP. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch Intern Med2000;160(15):2273–80
14.
IgelMSudhopTvon BergmannK. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol2001;57(5):357–64
15.
JacobSSJacobSWilliamsCDeegMA. Simvastatin, fenofibrate and rhabdomyolysis. Diabetes Care2005;28(5):1258
16.
de LemosJABlazingMAWiviottSD. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA2004;292(11):1307–16
17.
GrahamDJStaffaJAShatinD. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA2004;292(21):2585–90
18.
HansenKEHildebrandJPFergusonEESteinJH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med2005;165(22):2671–6
19.
YoungJMFlorkowskiCMMolyneuxSL. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol2007;100(9):1400–3
20.
McKenneyJJonesMAbbyS. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin2005;21(9):1403–12
21.
FarnierMFreemanMWMacdonellG. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J2005;26(9):897–905
22.
ZemaMJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther2005;12(4):306–10
